CRISPR Therapeutics (CRSP) Financial Analysis & Valuation | Quarter Chart
CRISPR Therapeutics (CRSP)
CRSPPrice: $53.52
Fair Value: 🔒
🔒score
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allo... more
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serio... more
Description
Shares
| Market Cap | $5.14B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CH | CEO | Samarth Kulkarni |
| IPO Date | 2016-10-19 | CAGR | — |
| Employees | 393 | Website | www.crisprtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CRSP chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.76B | P/E Ratio | -10.5 |
| Forward P/E | -12.23 | PEG Ratio | — |
| P/S Ratio | 1962.24 | P/B Ratio | 2.5 |
| P/CF Ratio | -13.95 | P/FCF Ratio | -14.85 |
| EPS | $-5.54 | EPS Growth 1Y | 49.2% |
| EPS Growth 3Y | -22.1% | EPS Growth 5Y | 23.02% |
| Revenue Growth 1Y | -92.73% | Gross Margin | -85.6% |
| Operating Margin | -253.85% | Profit Margin | -222.15% |
| ROE | -0.32% | ROA | -0.26% |
| ROCE | -0.31% | Current Ratio | 13.25 |
| Quick Ratio | 13.25 | Cash Ratio | 2.38 |
| Debt/Equity | 0.21 | Interest Coverage | — |
| Altman Z Score | 7.78 | Piotroski Score | 1 |